# C_2015066EN.01001001.xml

| 24.2.2015 | EN | Official Journal of the European Union | C 66/10 |
| --- | --- | --- | --- |

24.2.2015

EN

Official Journal of the European Union

C 66/10

---

Prior notification of a concentration

(Case M.7480 — Actavis/Allergan)

(Text with EEA relevance)

(2015/C 66/11)

| 1. | On 9 February 2015, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Actavis plc (‘Actavis’, Ireland) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Allergan Inc. (‘Allergan’, US) by way of purchase of shares. |
| --- | --- |

1.

On 9 February 2015, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which Actavis plc (‘Actavis’, Ireland) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of Allergan Inc. (‘Allergan’, US) by way of purchase of shares.

1

| 2. | The business activities of the undertakings concerned are:
  —   for Actavis: development, manufacturing, marketing, sale and distribution of a wide range of pharmaceutical products, with a particular focus on diseases of the central nervous system, gastroenterology, women’s health, urology, cardiovascular, respiratory and anti-infective therapy,
  —   for Allergan: development, manufacturing, marketing, sale and distribution of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, specifically for the fields of ophthalmology, neurology, medical aesthetics (including breast aesthetics), medical dermatology and urology. |
| --- | --- |

2.

The business activities of the undertakings concerned are:

—   for Actavis: development, manufacturing, marketing, sale and distribution of a wide range of pharmaceutical products, with a particular focus on diseases of the central nervous system, gastroenterology, women’s health, urology, cardiovascular, respiratory and anti-infective therapy,

for Actavis

—   for Allergan: development, manufacturing, marketing, sale and distribution of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, specifically for the fields of ophthalmology, neurology, medical aesthetics (including breast aesthetics), medical dermatology and urology.

for Allergan

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7480 — Actavis/Allergan, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7480 — Actavis/Allergan, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

---